BLSM.US BlossomHill Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
14.02 USD
Close of Nov 14, 2026
11.02 27.99
Market cap
USD 446M
P/E
-
P/B
-
ROE
-43.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BLSM.US undervalued?

Graham number

The Graham number of BlossomHill Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BlossomHill Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for BlossomHill Therapeutics, Inc. Common Stock yet.

BlossomHill Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BlossomHill Therapeutics, Inc. Common Stock

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myel…

Full company profile